Trial Profile
A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously. Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs RG 6146 (Primary)
- Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 14 Dec 2020 Results evaluating the safety, pharmacokinetics (PK), pharmacodynamics and clinical activity, published in the British Journal of Cancer.
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 03 Apr 2017 Planned End Date changed from 1 Aug 2017 to 31 Dec 2017.